Search

The article highlights the meeting of the Forum on Lipids in Clinical Medicine that was held in Great Britain. Speaker D. N. Brindley presented a paper on hepatic lipid and lipoprotein metabolism. T. J. Peters of MRC Clinical Research Centre and his group provided an insight into the causes of fatty liver. J. Owen of Royal Free Hospital School discussed the surface composition of plasma lipoproteins.

Guidelines for the management of either hypertension or hyperlipidaemia have been widely published. However, recent data have shown the high frequency of an abnormal lipid profile in hypertensive subjects. We have therefore surveyed 195 general practitioners throughout Britain to determine current community- based attitudes and management approaches to hypertension with coexistent hypercholesterolaemia. Routine screening for lipids in hypertensive subjects was recommended by 40% of respondents. First-line antihypertensive drug choices were influenced by the knowledge of a hypercholesterolaemia, with preference for drugs known to have no adverse effects on the lipid profile. When first-choice drug failed to effectively lower blood pressure, the additional drug or the substitute choices were not influenced by the metabolic profiles of the alternative selected. The current wide choice of antihypertensive drugs and the complexity of metabolic complications of treatment plus the relationship of risk factor clustering has made the formulation of management strategies very difficult. This was supported by the finding that 88% of respondents in our survey felt that there was a clear need for consensus management guidelines for the treatment of hypertension with coexistent hyper-cholesterolaemia. [ABSTRACT FROM AUTHOR]